Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.neulandlabs.com | |
Market Cap | 1,317.31 Cr. | |
Enterprise Value(EV) | 1,529.95 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 49.74 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | 20.67 | Trailing Twelve Months Ending 2022-03 |
Industry PE | 29.26 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 654.40 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 1.57 | Calculated using Price: 1,028.35 |
Dividend Yield | 0.49 | Period Ending 2021-03 |
No. of Shares Subscribed | 1.28 Cr. | 12,829,889 Shares |
FaceValue | 10 | |
Company Profile | ||
Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees. It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years. Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients. Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing. The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe. Product range of the company includes:
Achievements/ recognition:
|
1 Day |
|
+0.43% |
1 Week |
|
-1.20% |
1 Month |
|
-26.53% |
3 Month |
|
-8.59% |
6 Month |
|
-39.34% |
1 Year |
|
-54.46% |
2 Year |
|
+150.39% |
5 Year |
|
-27.08% |
10 Year |
|
+1401.90% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 15.92 | 24.14 | 11.24 | 15.64 | 22.34 | 5.02 | 3.48 | 2.30 | 10.79 | |
Return on Capital Employed (%) | 15.58 | 18.99 | 15.75 | 18.57 | 15.98 | 4.07 | 3.99 | 7.85 | 12.81 | |
Return on Assets (%) | 3.26 | 5.89 | 3.20 | 5.23 | 6.65 | 1.23 | 1.49 | 1.37 | 6.31 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
Shh. Funds | 100 | 124 | 161 | 187 | 546 | 558 | 699 | 710 | 786 | 841 | |
Non Curr. Liab. | 62 | 52 | 55 | 69 | 54 | 146 | 104 | 163 | 170 | 180 | |
Curr. Liab. | 263 | 307 | 295 | 268 | 286 | 367 | 327 | 358 | 369 | 363 | |
Minority Int. | 0 | 0 | 0 | ||||||||
Equity & Liab. | 425 | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | |
Non Curr. Assets | 198 | 196 | 196 | 210 | 511 | 624 | 677 | 716 | 775 | 801 | |
Curr. Assets | 227 | 288 | 316 | 314 | 375 | 447 | 453 | 515 | 550 | 583 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 425 | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
Net Sales | 461 | 466 | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | |
Other Income | 4 | 3 | 1 | 2 | 1 | 5 | 3 | 4 | 16 | 5 | |
Total Income | 465 | 469 | 470 | 512 | 580 | 532 | 670 | 767 | 953 | 956 | |
Total Expenditure | -403 | -395 | -403 | -430 | -473 | -477 | -608 | -661 | -790 | -811 | |
PBIDT | 62 | 74 | 67 | 82 | 108 | 55 | 62 | 106 | 163 | 145 | |
Interest | -31 | -25 | -27 | -24 | -21 | -19 | -16 | -22 | -18 | -14 | |
Depreciation | -15 | -15 | -15 | -16 | -19 | -22 | -26 | -31 | -40 | -49 | |
Taxation | -2 | -8 | -9 | -15 | -20 | -2 | -4 | -37 | -25 | -18 | |
Exceptional Items | |||||||||||
PAT | 14 | 27 | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | |
Minority Interest | 0 | 0 | 0 | 0 | |||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 14 | 27 | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | |
Adjusted EPS | 17 | 33 | 18 | 31 | 53 | 14 | 13 | 13 | 63 | 49 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 49 | 26 | 49 | 13 | 45 | 39 | 11 | 70 | 57 | 189 | |
Cash Fr. Inv. | -5 | -7 | -10 | -14 | -20 | -42 | -116 | -77 | -49 | -84 | |
Cash Fr. Finan. | -44 | -20 | -39 | 1 | -24 | 0 | 105 | 12 | -5 | -114 | |
Net Change | 0 | -1 | 0 | 0 | 1 | -4 | 0 | 5 | 3 | -9 | |
Cash & Cash Eqvt | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 8 | 11 | 2 |
Thu, 19 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Reg.24A-Annual Secretarial Compliance Report for the year ended March 31 2022 |
Wed, 11 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication Neuland Laboratories Limited has informed the Exchange about Newspaper Advertisements |
Tue, 10 May 2022
Board Meeting Outcome for Outcome Of Board Meeting Audited Results And Recommendation Of Final Dividend For The Year Ended March 31 2022 Outcome of Board Meeting Audited results and recommendation of final dividend for the year ended March 31 2022 |
Fri, 20 May 2022 |
|
|
|
|
|